These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 35212878)

  • 1. Effects and Trends in Opioid-Related Promotional Payments Between 2014 and 2019: a Panel Data Analysis Among Prescribers in Medicare Part D.
    Pope E; Sehgal N
    J Gen Intern Med; 2022 Oct; 37(13):3509-3511. PubMed ID: 35212878
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmaceutical payments to physicians may increase prescribing for opioids.
    Nguyen TD; Bradford WD; Simon KI
    Addiction; 2019 Jun; 114(6):1051-1059. PubMed ID: 30667135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Payments from drug companies to physicians are associated with higher volume and more expensive opioid analgesic prescribing.
    Zezza MA; Bachhuber MA
    PLoS One; 2018; 13(12):e0209383. PubMed ID: 30566426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disclosure of industry payments to prescribers: industry payments might be a factor impacting generic drug prescribing.
    Qian J; Hansen RA; Surry D; Howard J; Kiptanui Z; Harris I
    Pharmacoepidemiol Drug Saf; 2017 Jul; 26(7):819-826. PubMed ID: 28485111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Provider-directed marketing may increase prescribing of medications for opioid use disorder.
    Nguyen T; Andraka-Christou B; Simon K; Bradford WD
    J Subst Abuse Treat; 2019 Sep; 104():104-115. PubMed ID: 31370974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Pharmaceutical Manufacturer Payments to Physicians and Prescribing Dosage of Opioids.
    Fleischman W; Agrawal S; Gross CP; Ross JS
    J Gen Intern Med; 2019 Jul; 34(7):1074-1076. PubMed ID: 31011967
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmaceutical opioid marketing and physician prescribing behavior.
    Beilfuss S; Linde S
    Health Econ; 2021 Dec; 30(12):3159-3185. PubMed ID: 34562329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between industry payments and prescribing costly medications: an observational study using open payments and medicare part D data.
    Sharma M; Vadhariya A; Johnson ML; Marcum ZA; Holmes HM
    BMC Health Serv Res; 2018 Apr; 18(1):236. PubMed ID: 29609611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Naloxone Prescribing Among Frequent Opioid Prescribers in Medicare Part D from 2013 to 2017: a Retrospective Study.
    Roberts AW
    J Gen Intern Med; 2021 Feb; 36(2):543-545. PubMed ID: 32378012
    [No Abstract]   [Full Text] [Related]  

  • 10. Association between industry payments for opioid products and physicians' prescription of opioids: observational study with propensity-score matching.
    Inoue K; Figueroa JF; Orav EJ; Tsugawa Y
    J Epidemiol Community Health; 2020 Aug; 74(8):647-654. PubMed ID: 32350126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations between pharmaceutical industry payments to physicians and prescription of PARP inhibitors in the United States.
    Murayama A; Marshall DC
    Gynecol Oncol; 2024 Feb; 181():83-90. PubMed ID: 38147713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The lack of a relationship between physician payments from drug manufacturers and Medicare claims for abiraterone and enzalutamide.
    Bandari J; Ayyash OM; Turner RM; Jacobs BL; Davies BJ
    Cancer; 2017 Nov; 123(22):4356-4362. PubMed ID: 28749536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promotional Payments Made to Urologists by the Pharmaceutical Industry and Prescribing Patterns for Targeted Therapies.
    Hollenbeck BK; Oerline M; Kaufman SR; Caram MEV; Dusetzina SB; Ryan AM; Shahinian VB
    Urology; 2021 Feb; 148():134-140. PubMed ID: 33075381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of psychiatrists' prescription of opioid, benzodiazepine, and buprenorphine in Medicare Part D in the United States.
    Pan K; Silver S; Davis C
    Trends Psychiatry Psychother; 2020; 42(1):48-54. PubMed ID: 32321084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emergency Providers' Opioid Prescribing Behaviors Among Medicare Part D Beneficiaries in North Carolina, 2013-2014: Medication Utilization and Costs.
    Williams B; Mospan G; Seabock R; Gillette C; DeGeeter M
    N C Med J; 2018; 79(3):143-148. PubMed ID: 29735614
    [No Abstract]   [Full Text] [Related]  

  • 16. Association Between Payments by Pharmaceutical Manufacturers and Prescribing Behavior in Rheumatology.
    Duarte-García A; Crowson CS; McCoy RG; Herrin J; Lam V; Putman MS; Ross JS; Matteson EL; Shah ND
    Mayo Clin Proc; 2022 Feb; 97(2):250-260. PubMed ID: 35120693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promoting interprofessional collaboration: pharmacy students teaching current and future prescribers about Medicare Part D.
    Lai CJ; Smith AR; Stebbins MR; Cutler TW; Lipton HL
    J Manag Care Pharm; 2011; 17(6):439-48. PubMed ID: 21787029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between industry payments and prescriptions of long-acting insulin: An observational study with propensity score matching.
    Inoue K; Tsugawa Y; Mangione CM; Duru OK
    PLoS Med; 2021 Jun; 18(6):e1003645. PubMed ID: 34061852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Pharmaceutical Industry Payments to Physicians With Prescription and Medicare Expenditures for Pimavanserin.
    Mehta HB; Moore TJ; Alexander GC
    Psychiatr Serv; 2021 Jan; 72(1):77-80. PubMed ID: 32838675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opioid Prescriptions by Pain Medicine Physicians in the Medicare Part D Program: A Cross-Sectional Study.
    Goel V; Moran B; Kaizer AM; Sivanesan E; Patwardhan AM; Ibrahim M; DeWeerth JC; Shannon C; Shankar H
    Anesth Analg; 2021 Jun; 132(6):1748-1755. PubMed ID: 33591120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.